# A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis

> **NCT00375596** · PHASE2 · WITHDRAWN · sponsor: **Bausch & Lomb Incorporated**

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Ketotifen/vasoconstrictor

## Key facts

- **NCT ID:** NCT00375596
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn without starting or enrolling subjects due to a business decision to not proceed with the project.
- **Last updated:** 2015-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00375596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00375596, "A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00375596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*